Selective serotonin reuptake inhibitor fluoxetine, reduces solid tumor burden and metastasis through activation of host antitumor immune response and modulation of tumor microenvironment | Synapse
March 3, 2026
Selective serotonin reuptake inhibitor fluoxetine, reduces solid tumor burden and metastasis through activation of host antitumor immune response and modulation of tumor microenvironment
Puntos clave
Fluoxetine significantly reduces tumor burden and metastasis, indicating its potential as an antitumor agent.
In preclinical models, tumor size decreased by up to 40%, showing notable effects on growth suppression.
Assessment of immune cell activation demonstrated a marked increase in antitumor immune responses.
These findings suggest fluoxetine may offer new therapeutic strategies for treating solid tumors, pending further research.